Hepatitis C Therapy

Phase II clinical study initiated for IDN-6556 in hepatitis C

Published in Hepatitis Weekly, August 16th, 2004

Idun Pharmaceuticals, Inc., has initiated a phase II clinical study of IDN-6556 in patients infected with hepatitis C virus (HCV).

The dose-response study will evaluate whether IDN-6556 can decrease the liver damage that occurs from hepatitis, an inflammation of the liver, which can be caused by HCV infection.

Participants in this trial will have previously failed to respond to existing drugs for HCV and will receive one of several doses of IDN-6556, or placebo, given orally as a monotherapy for 3 months. This study will be conducted at 15 sites in the U.S. and is expected to enroll up to 200 patients.

"The initiation of this...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2004-08-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry